Author: Skeik, Nedaa; Smith, Jenna E.; Patel, Love; Mirza, Aleem K.; Manunga, Jesse M.; Beddow, David
Title: Risk and Management of Venous Thromboembolism in Patients with COVID-19 Cord-id: 8agx8jd8 Document date: 2020_12_14
ID: 8agx8jd8
Snippet: OBJECTIVE: One of the most pronounced and poorly understood pathological features of COVID-19 infection has been high risk for venous and arterial thromboembolic complications. An increasing number of thromboembolic events are being reported almost on a daily basis, and the medical community has struggled to predict and mitigate this risk. We aimed to review available literature on the risk and management of COVID-19 related venous thromboembolism (VTE), and provide evidence-based guidance to ma
Document: OBJECTIVE: One of the most pronounced and poorly understood pathological features of COVID-19 infection has been high risk for venous and arterial thromboembolic complications. An increasing number of thromboembolic events are being reported almost on a daily basis, and the medical community has struggled to predict and mitigate this risk. We aimed to review available literature on the risk and management of COVID-19 related venous thromboembolism (VTE), and provide evidence-based guidance to manage these events. METHODS: A literature review of VTE complications in patients with COVID-19 was performed, in addition to a summary of the societal guidelines and present pathways implemented at our institution for the management of both in- and outpatient COVID-19 related VTE. RESULTS: While a significant VTE risk has been confirmed in patients with COVID-19, literature addressing best ways to mitigate this risk is lacking. Furthermore, there has been very limited guidance provided by societal guidelines to help prevent and manage VTE associated with the COVID-19 infection. In light of the available data, we advise that all patients admitted with suspected or confirmed COVID-19 receive pharmacological prophylaxis if bleeding risk is acceptable. For patients with COVID-19 who have been discharged from the emergency department or hospital, we suggest extended thromboprophylaxis (up to 39 days) as long as bleeding risk is low. CONCLUSION: We believe that this literature summary along with our center recommendations and algorithms provide valuable guidance to providers caring for patients with COVID-19 related VTE. More research is needed to standardize prophylaxis and management protocols for these patients.
Search related documents:
Co phrase search for related documents- active cancer and additional support: 1, 2
- active cancer and admission dimer: 1
- active cancer and lopinavir ritonavir: 1, 2, 3
- active cancer and low risk patient: 1
- acute respiratory syndrome sars and additional support: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute respiratory syndrome sars and additional support need: 1
- acute respiratory syndrome sars and admission dimer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute respiratory syndrome sars and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome sars and low risk patient: 1, 2, 3, 4
- acutely ill and admission dimer: 1
- acutely ill and low risk patient: 1
- acutely ill and magellan trial: 1
- additional support and lopinavir ritonavir: 1
- admission dimer and lopinavir ritonavir: 1
Co phrase search for related documents, hyperlinks ordered by date